

Position Paper of the Florida Academy of Pain Medicine on Regenerative Injection Therapy: Effectiveness and Appropriate Usage

Voted and accepted by the Florida Academy of Pain Medicine membership at the Annual Conference at the Hyatt Regency Tampa, Florida, on Saturday, June 30, 2001.

Position Paper Committee Members:

Felix S. Linetsky, MD, private practice, Palm Harbor, Florida, Clinical Associate Professor, Department of Family Medicine, Nova Southeastern College of Osteopathic Medicine Assistant Professor, Department of Anatomy, University of South Florida College of Medicine

Kenneth Botwin, MD, private practice, Florida Spine Institute, Clearwater

Lawrence Gorfine, MD, private practice, Lake Worth

Gary W. Jay, MD, private practice, Orlando

Raphael Miguel, MD, Professor and Chief of Anesthesiology Service, H. Lee Moffit Cancer Center, Director of Pain Management Fellowship Program, Professor of Anesthesia, University of South Florida College of Medicine, Tampa

Asya Mikulinsky, MD, private practice, Miami

Winston Parris, MD, private practice, Clinical Professor of Anesthesiology, University of South Florida, Tampa, Adjunct Professor of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee

Sanford Pollack, D0, private practice, Jacksonville

Albert Ray, MD, private practice, Miami

Lloyd Saberski, MD, Medical Staff Attending, Yale-New Haven Hospital, New Haven, Connecticut

Peter Taraschi, D0, private practice, Palm Bay

Francisco Torres, MD, private practice, Florida Spine Institute, Clearwater

Andrea Trescot, MD, private practice, Jacksonville

The Florida Academy of Pain Medicine endorses regenerative injection therapy and supports its usage for chronic pain associated with sprained or strained ligaments or tendons, repetitive motion disorders, postural pain, and recurrent somatic dysfunctions resulting from lax ligaments.

Regenerative injection therapy (RIT), also known as prolotherapy, is an interventional technique for the

Treatment of chronic pain due to connective tissue diathesis by induction of collagen chemomodulation through inflammatory, proliferative, and regenerative/repairative responses mediated by multiple growth factors." The purpose of this position paper is to:

1. Inform the members of the Florida Academy of Pain Medicine (FAPM) and the medical community at large

regarding the validity of an under-utilized type-specific treatment for chronic musculoskeletal pain related to connective tissue pathology.

2. Outline common indications and conditions treated with RIT, as well as contraindications thereto.

3. Encourage the use of RIT for the treatment of appropriate painful pathology of the connective tissue.



METHODOLOGY

To determine the validity of RIT, a committee of interventional pain physicians was formed to review pertinent literature. The committee reviewed 78 articles, 9 complete textbooks, and 51 relevant articles and chapters from additional textbooks.

FINDINGS

From 1937 through 2000, more than 40 publications reported case studies and retrospective, prospective, and animal studies evaluating the results of RIT treatment. The studies reported the findings of RIT treatment of more than 530,000 patients. Improvement based on return to work and restoration of functional and occupational activities occurred in 48% to 82% of the patients. Resolution of pain ranged from 0% to 100%. Complications included pneumothorax (28), chest tube placement (2), allergic reaction (24), grand mal seizure (1), and aseptic meningitis (1).

The findings of the FAPM committee substantially contrast with the position of Florida Workmen's Compensation and the Health Care Financing Administration (HCFA) Medicare guidelines, section 35-13, which states that "Prolotherapy, joint sclerotherapy, and ligamentous injections with sclerosing agents—not covered... the effectiveness of these therapies has not been verified by scientifically controlled studies."

(For further information, see <http://www.hcfa.gov/coverage/8b3.htm>.)

The committee recommends consideration of RIT as a type-specific treatment for post-traumatic, degenerative, overuse, and painful conditions of the musculoskeletal system related to the pathology of the connective tissue.

For decades, a small group of allopathic and osteopathic physicians has been practicing RIT. Pilot, retrospective, open-face prospective, and double-blind placebo-controlled studies have clearly indicated the effectiveness of RIT in the treatment of chronic musculoskeletal pain arising from post-traumatic and degenerative changes in connective tissue such as ligaments, tendons, fascia, and intervertebral discs.¹⁻¹⁰¹

Clinical and experimental electron microscopic studies have proved that newly formed connective tissue has biomechanical properties similar to those of normal ligaments and tendons.^{61,11,16,15} Preliminary results of clinical prospective trials for chemonucleo-annuloplasty with proliferation-causing substances show significant promise.^{14,11,64,14}

Conclusions reached in the literature and drawn from extensive clinical experience have found RIT an effective therapy for numerous chronic pain conditions. This position paper reviews the clinical and pathophysiological aspects of RIT. The Florida Academy of Pain Medicine endorses RIT when used appropriately for the treatment of specific chronic pain entities.

MECHANISM OF ACTION

The RIT mechanism of action is complex and multifaceted. The six currently identified components are:

1. The mechanical transection of cells and matrices induced by the needle causes cellular damage and stimulates an inflammatory cascade.^{1,6-1,11,19,102-104}
2. Compression of cells by the extracellular volume of the injected solution stimulates intracellular growth factors.^{6-1,101-101}
3. Chemomodulation of collagen through inflammatory proliferative, regenerative/repairative responses induced by the chemical properties of the proliferants and mediated by cytokines and multiple growth factors.^{3,6,33,37-39,105-108}
4. Chemoneuromodulation of peripheral nociceptors and antidromic, orthodromic, sympathetic, and axon reflex transmissions.^{3,6,43-50}
5. Modulation of local hemodynamics with changes in intraosseous pressure leading to the reduction of pain. Empirical observations suggest that a dextrose/lidocaine combination has a much more prolonged action than lidocaine' alone.^{6,43-50,109-111}
6. A temporary repetitive stabilization of the painful hypermobile joints, induced by the inflammatory response to the proliferants, provides a better environment for regeneration and repair of affected ligaments and tendons.^{3,4,6,26,27,37-41,91,92,94-97}

**PUTATIVE PAIN-GENERATING
STRUCTURES AFFECTED
BY RIT** ^{5-32,35-69,80-104,112-128}

2. Ligaments: Intra-articular, periarticular, capsular
3. Tendons
4. Fascia
5. Entheses: The zone of insertion of ligament, tendon, or articular capsule to bone
6. Intervertebral discs: The outer layers of the annulus represent a typical entheses.

TISSUE PATHOLOGY

1. Sprain: Ligamentous injury at the fibro-osseous junction or intersubstance disruption secondary to sudden or severe twisting of a joint with stretching or tearing of ligaments. ¹⁰⁷⁻¹²⁸⁻¹³⁰
2. Strain: Muscle/tendon injury at the fibromuscular or fibro-osseous interface. When concerned with peripheral muscles and tendons, sprains and strains are identified as separate injuries and in three stage gradations: first-, second- and third-degree sprain or strain. ²⁸⁻¹³⁰
3. Enthesopathy: A painful degenerative pathologic process that results in deposition of poorly organized tissue, degeneration and tendinosis at the fibro-osseous interface, and transition toward loss of function. ^{1,6,77,107,128,129}
4. Tendinosis/ligamentosis: A focal area of degenerative changes

owing to failure of cell matrix adaptation to excessive load and tissue hypoxia with a strong tendency toward chronic pain and dysfunction ^{.6,1,11,103,105-107-128}

5. Pathologic ligament laxity: A post-traumatic or congenital condition leading to painful hypermobility of the axial and peripheral joints ^{.3,1,11,26-32,35-40}

INDICATIONS ^{1-12,35-70,75-101,112-126,130,131}

1. Chronic pain from ligaments or tendons secondary to sprains or strains
2. Pain from overuse or occupational conditions known as repetitive motion disorders, ie, neck and wrist pain in typists and computer operators, tennis and golfers' elbow, and chronic supraspinatus tendinosis
3. Chronic postural pain of the cervical, thoracic, lumbar, and lumbosacral regions
4. Painful recurrent somatic dysfunctions secondary to ligament laxity that improves temporarily with manipulation. Painful hypermobility and subluxation at given peripheral or spinal articulation(s) or mobile segment(s) accompanied by a restricted range of motion at reciprocal segment(s)
5. Thoracic and lumbar vertebral compression fractures with a wedge deformity that exerts stress on the posterior ligamento-tendinous complex
6. Recurrent painful subluxations of ribs at the costotransverse,

costovertebral and/or costosternal articulations

7. Osteoarthritis of axial and peripheral joints, spondylosis, spondylolysis, and spondylolisthesis
8. Painful cervical, thoracic, lumbar, lumbosacral, and sacroiliac instability secondary to ligament laxity
9. Failed back surgery syndrome
10. Back pain refractory to radiofrequency and intradiscal electrothermal therapy procedures
11. Tendon, ligament, and synovial joint nociceptive sources. Not responding to anti-inflammatory treatment approach
12. Enhanced results of physical therapy and chiropractic/osteopathic manipulations

**SYNDROMES AND
DIAGNOSTIC ENTITIES
SUCCESSFULLY TREATED
WITH RIT** ^{2-32,35-70,74-132}

1. Cervicocranial syndrome (cervicogenic headaches, secondary to ligament sprain and laxity, atlanto-axial and atlanto-occipital joint sprains, mid-cervical zygapophyseal sprains)
2. Temporomandibular pain and muscle dysfunction syndrome
3. Barre-Lieou syndrome
4. Torticollis
5. Cervical segmental dysfunctions
6. Cervicobrachial syndrome (shoulder/neck pain)
7. Hyperextension/hyperflexion injury syndromes

8. Cervical, thoracic, and lumbar zygapophyseal syndromes
9. Cervical, thoracic, and lumbar sprain/strain syndrome
10. Costotransverse joint pain
11. Costovertebral arthrosis/dysfunction
12. Slipping rib syndrome
13. Sternoclavicular arthrosis and repetitive sprain
14. Thoracic segmental dysfunction
15. Tietze's syndrome
16. Costochondritis/chondrosis
17. Costosternal arthrosis
18. Xiphoidalgia syndrome
19. Acromioclavicular sprain/arthrosis
20. Shoulder hand syndrome
21. Recurrent shoulder dislocations
22. Scapulothoracic crepitus
23. Iliocostalis friction syndrome
24. Iliac crest syndrome
25. Iliolumbar syndrome
26. Internal lumbar disc disruption
27. Interspinous pseudoarthrosis (Baastrup's disease)
28. Lumbar instability
29. Lumbar ligament sprain
30. Spondylolysis
31. Sacroiliac joint pain
32. Sacrococcygeal joint pain
33. Gluteal tendinosis
34. Trochanteric tendinosis
35. Myofascial pain syndromes
36. Ehlers-Danlos syndrome
37. Osgood-Schlatter disease
38. Ankylosing spondylitis (Marie-Strumpell disease)
39. Failed back syndrome
40. Fibromyalgia syndrome
41. Baker's cyst
42. Foot and/or ankle
 - Sinus tarsi syndrome
 - Metatarsalgia

- Chronic ankle sprain
- Instability
- Laxity of ligaments

CONTRAINDICATIONS

1. Allergy to anesthetic or proliferant solutions or their ingredients such as dextrose, sodium morrhuate, or phenol
2. Acute non-reduced subluxations or dislocations
3. Acute arthritis (septic or post-traumatic with hemarthrosis)
4. Acute bursitis or tendinitis
5. Capsular pattern shoulder and hip designating acute arthritis accompanied by tendinitis
6. Acute gout or rheumatoid arthritis
7. Recent onset of a progressive neurologic deficit involving the segment to be injected, including, but not limited to (severe intractable cephalgia, unilaterally dilated pupil, bladder dysfunction, bowel incontinence)
8. Requests for a large quantity of sedation and/or narcotics before and after treatment
9. Paraspinal neoplastic lesions involving the musculature and osseous structures
10. Severe exacerbation of pain or lack of improvement after infiltration of the putative nociceptive structure with a local anesthetic
- H. Any acute medical or surgical condition that renders the patient's status unstable
12. Infection or neoplasia overlying the area of injection

COMMONLY USED SOLUTIONS

The most common solutions for injection therapy are dextrose based. Dilutions can be made with local anesthetic (eg, 1 mL 50% dextrose plus 3 mL 1% lidocaine). Gradual progression to 25% dextrose solution can be considered.^{4-8,22}

For intra-articular injection of the knee, a 25% dextrose solution had been used for decades.⁴ Recently, a 10% dextrose solution has been investigated and has proved effective." The 5% sodium morrhuate contains sodium salts of saturated and unsaturated fatty acids of cod liver oil and 2% benzyl alcohol. Note that the benzyl alcohol is chemically similar to phenol and acts as a local anesthetic and preservative.^{4,6,11,77,94}

Dextrose phenol glycerin solution consists of 25% dextrose, 2.5% phenol, and 25% glycerin. In all referenced studies, it was diluted with a local anesthetic of the practitioner's choice before injection. Dilution reported ratios are 1:1, 1:2, and 2:3.^{10,19,20,21,118} The 6% phenol in glycerin solution was used at donor harvest sites of the iliac crests for neurolytic and proliferative responses.^{72,101} Other solutions include pumice suspension, tetracycline, a mixture of chondroitin sulfate, glucosamine sulfate with dextrose, and Plasmogel "Q-U".^{4,15,25,30-32,64,126}

CONCLUSIONS

1. Regenerative injection therapy, also known as prolotherapy, is valuable for the treatment of chronic painful conditions of the

- locomotive systems.
2. Thorough familiarity of normal, pathologic, cross-sectional, and clinical anatomy, as well as anatomical variations and functions is necessary to ensure appropriate technique.
 3. Current literature supports manipulation under local joint anesthesia and a series of local anesthetic blocks for somatic pain.
 4. Use of RIT in an ambulatory setting is an acceptable standard of care in the community.
 5. Current literature suggests that NSAIDs and steroid preparations have limited use in chronic painful overuse conditions and in degenerative painful conditions of ligaments and tendons: however, they are occasionally helpful to curb a significant inflammatory reaction to proliferants. Microinterventional regenerative techniques and proper rehabilitation up to 6 months or 1 year, supported with mild opioid analgesics, may be more appropriate.

SUMMARY

RIT is a safe and effective treatment modality that is very useful in a significant number of pain syndromes arising from ligament and tendon diathesis, as well as other clearly delineated pain problems. Physicians who use RIT must be knowledgeable in clinical anatomy and function and should be properly trained in this technique via a combination of

seminars or workshops, apprenticeships, or visiting fellowships to safely and effectively use this treatment. The Florida Academy of Pain Medicine endorses RIT, when administered appropriately for the treatment of specific chronic pain entities.

REFERENCES

1. Cotran RS, Kumar V, Collins T. *Robbins Pathologic Basis of Disease*. Philadelphia, Pa: WB Saunders; 1999.
2. Dorman TA, Ravin TH. *Diagnosis and Injection Techniques in Orthopedic Medicine*. Baltimore, MD: Williams & Wilkins; 1991.
3. Hackett GS, Hemwall GA, Montgomery GA. *Ligament and Tendon Relaxation-Treated by Prolotherapy*. 5th ed. Springfield, Ill: Charles C. Thomas; 1991.
4. Hackett GS. *Ligament and Tendon Relaxation-Treated by Prolotherapy*. 3rd ed. Springfield, Ill: Charles C. Thomas; 1958.
5. Linetsky F, Saberski L, Miguel R, Snyder A. A history of application in pain management: Part II, 1960s-1980s. *Pain Clin*. 2001;3:32-36.
6. Linetsky F, Miguel R, Saberski L. Pain management with regenerative injection therapy (RIT). In: Weiner RS, ed. *Pain Management: A Practical Guide for Clinicians*. 6th ed. Washington, DC: CRC Press; 2002.
7. Reeves KD. Prolotherapy: basic science clinical studies and technique. In: Lennard TA, ed. *Pain Procedures in Clinical Practice*. Philadelphia, Pa: Hanley and Belfus Inc; 2000.
8. Reeves KD. Prolotherapy: present and future applications in soft-tissue pain and disability. *Phys Med Rehab Clin North Am*. 1995;6:917-926.
9. Bahme B. Observations on the treatment of hypermotile joints by injection. *J Am Osteopath Assoc*. November 1945; 45:101-109.
10. Barbor R. A treatment for chronic low back pain. Presented at: Fourth International Congress of Physical Medicine; September 6-11. 1964; Paris, France.
11. Biegeleisen HL. *Varicose Veins, Related Diseases and Sclerotherapy: A Guide for Practitioners*. Montreal, Canada: Eden Press; 1984.
12. Blaschke J. Conservative management of intervertebral disk injuries. *J OK State Med Assoc*. 1961;54:144-151.
13. Blumenthal L. Injury to the cervical spine as a cause of headache. *Postgrad Med*. 1974;56:3.
14. Bourdeau Y. Five-year follow-up on sclerotherapy/prolotherapy for low back pain. *Manual Med*. 1988;3:155-157.
15. Chase R. Basic sclerotherapy. *Osteopath Ann*. 1978;6:12-15.
16. Coleman AH. Physician electing to treat by prolotherapy alters the method at his peril. *J Nail Med Assn*. 1968;60:346-348.
17. Compere EL, Kernahan WT. Persistent backache. *Med Clin North Am*. 1958;42:299-307.
18. Coplans C. The use of sclerosant injections in ligamentous pain. In: Heflet A, Grueble L, David M, eds. *Disorders of the Lumbar Spine*. Philadelphia, Pa: Lippincott Co; 1972.
19. Cyriax J. Diagnosis of soft tissue lesion. In: Cyriax J, ed. *Textbook of Orthopaedic Medicine*. London, England: Bailliere Tindall; 1982.
20. Cyriax J. *Textbook of Orthopaedic Medicine*. 5th ed. Baltimore, MD: Williams & Wilkins; 1969.
21. Dorman T. Storage and release of elastic energy in the pelvis: dysfunction, diagnosis and treatment. In: Vleeming A, Mooney V, Snijders C, Dorman T, eds. *Low Back Pain and its Relation to the Sacroiliac Joint*. San Diego, Calif: Philips Medical Systems; 1992.
22. Dorman T. Prolotherapy: a survey. *J Orthop Med*. 1993;15:49-50.
23. Dorman T. *Prolotherapy in the Lumbar Spine and Pelvis*. Philadelphia,



- Pa: Hanley and Belfus Inc; 1995.
24. Eck B. New directions in the treatment of disc pain. Presented at: Annual Meeting of the International Spinal Injection Society; August 16, 1996; Vancouver, British Columbia.
25. Eek B. Intradiscal injection therapy for chronic discogenic pain, a prospective trial. Presented at: Annual Meeting of the American Association of Orthopedic Medicine; April 2001; Memphis, Tenn.
26. Gedney E. Special technic hypermobile joint: a preliminary report. *Osten Prof.* June 1937:30-31.
27. Gedney E. The hypermobile joint. Further reports on injection method. Read before the Osteopathic Clinical Society of Pennsylvania, Philadelphia. Pa. February 13, 1938.
28. Gedney E. Disc syndrome. *Osten Prof.* September 1951:11-15. 38-46, 50.
29. Gedney E. Use of sclerosing solution may change therapy in vertebral disk problem. *Osteo Prof* April 1952:11-13, 34-40.
30. Gedney E. Technic for sclerotherapy in the management of hypermobile sacroiliac. *Osten Prof* August 1952: 16-19, 37-38.
31. Gedney E. Progress report on use of sclerosing solutions in low back syndromes. *Osteo Prof.* August 1954:18-21, 40-44.
32. Gedney E. The application of sclerotherapy in spondylolisthesis and spondylolysis. *Osten Prqf.* September 1964:66-69, 102-105.
33. Williams PL, Bannister LH, Barry MM, et al. *Gray's v Anatomy*. 38th ed. New York, NY: Churchill Livingstone-, 1995.
34. Grayson ME Sterile meningitis after lumbosacral ligament sclerosing injections. *J Orthop Med.* 1994;16:98-99.
35. Green S. Hypermobility of joints: causes, treatment and technic of sclerotherapy. *Osteo Prof.* April 1956:26-27, 42-47.
36. Green S. The study of ligamentous tissue is regarded as key to sclerotherapy. *Osteo Prof* January 1958:26-29.
37. Hackett GS. Joint stabilization through induced ligament sclerosis. *Ohio State Med .l.* 1953;49:877-884.
38. Hackett GS, Henderson DG. Joint Stabilization: an experimental, histologic study with comments on the clinical application in ligament proliferation. *Am .l Surg.* 1955:89:968-973.
39. Hackett GS. *Joint Ligament Relaxation Treated by Fibro-osseous Proliferation*. Springfield, IJ]: Charles C. Thomas; 1956.
40. Hackett GS. Ligament relaxation and osteo-arthritis (loose jointed vs close jointed). *Rheumatism.* 1958;15:28-33.
41. Hackett GS. Low back pain. *Indust Med Surg.* 1959-,28:416-419.
42. Hackett GS. Prolotherapy in whiplash and low back pain. *Postgrad Med.* 1960; 27:214-219.
43. Hackett GS. Prolotherapy in low back pain from ligament relaxation and bone dystrophy. *Clin Med.* 1960;7:2551-256 1.
44. Hackett GS, Huang TC, Raftery A, Dodd TJ. Back pain following trauma and disease-prolotherapy. *Mil Med.* 1961;126:517-525.
45. Hackett GS, Huang TC. Prolotherapy for sciatica from weak pelvic ligaments and bone dystrophy. *Clin Med.* December 1961;8:2301-2316.
46. Hackett GS, Huang TC. Prolotherapy for headache: pain in the head and neck, and neuritis. *Headache.* 1962;2:20-28.
47. Hackett GS. Arteriosclerosis, carcinogenesis, neuritis and osteoporosis. *Angiology.* 1966;17:109-118.
48. Hackett GS. Cause and mechanism of headache, pain and neuritis. *Headache.* 1966;6:88-92.
49. Hackett GS. Uninhibited reversible antidromic vasodilation in pathophysiologic diseases: arteriosclerosis, carcinogenesis, neuritis and osteoporosis. *Angiology.* 1966:17:109-118.
50. Hackett GS. Uninhibited reversible antidromic vasodilatation in bronchiogenic pathophysiologic diseases. *Lancet.* 1966;86:398-404.
51. Hackett GS. Prevention of cancer, heart, lung and other diseases. *Clin Med.* 1967;74:19.
52. Haldeman KO, Soto-Hall R. The diagnosis and treatment of sacroiliac conditions by the injection of procaine (novocain). *J Bone Joint Surg.* 1938; 20:675-685.
53. Hirsch C. An attempt to diagnose the level of a disc lesion clinically by disc puncture. *Acta Orthop Scand.* 1948; 18:131-140.
54. Hirschberg G, Nacim F, Froetscher L. Treatment of the chronic iliolumbar syndrome by infiltration of the iliolumbar ligament. *Western .l Med.* 1992:136: 372-374.
55. Hirschberg G, Williams KA. Byrd JG. Diagnosis and treatment of iliocostal friction syndromes. *.l Orthop Med.* 1992: 14:35-39.
56. Kayfetz DO, Blumenthal I.S. Hackett GS, Hemwall GA, Neff FE. Whiplash injury and other ligamentous headache--its management with prolotherapy. *Headache.* 1963;3:1.
57. Kayfetz D. Occipito-cervical (whiplash) injuries treated by prolotherapy. *Med Trial Tech Q.* June 1963;147-167.
58. Kellgren JH. On the distribution of pain arising from deep somatic structures with charts of segmental pain areas. *Somatic Pain.* 1939;4:35-46.
59. Kidd R. Recent developments in the understanding of Osgood-Schlatter disease: a literature review. *J Orthop Med.* 1993;15:59-61.
60. Kidd R. Treatment of Osgood-Schlatter disease by prolotherapy: a case report. *J Orthop Med.* 1993;15:62-63.
61. Klein RG, Dorman TA, Johnson CE. Proliferation injections for low back pain: histologic changes of injected ligaments & objective measurement-, of lumbar spine mobility before & after treatment. *J Neurol Orthop Med Surg.* 1989;10: 123-126.
62. Klein RG, Eek BC. Prolotherapy: an alternative approach to managing low back pain. *J Musculoskel Med.* May 1997:45-59.
63. Klein RG. Diagnosis and treatment of gluteus medius syndrome. *J Orthop Med.* 1991;13:73-76.

64. Klein RG. Intradiscal injection therapy for chronic discogenic pain, a prospective trial in progress. Presented at a workshop sponsored by the American Association of Orthopedic Medicine; February 2001; Daly City, California.
65. Klein RG, Eek BC, DeLong WB, Mooney V. A randomized double-blind trial of dextrose-glycerin-phenol injections for chronic, low back pain. *J Spinal Disord.* 1993;6:23-33.
66. Koudele CJ. Treatment of joint pain. *Osteo Ann.* 1978;6:42-45.
67. Leedy R, Kulik AL. Analysis of 50 low back cases 6 years after treatment by joint ligament sclerotherapy. *Osteo Med.* 1976;6:15-2.
68. Leedy R. Applications of sclerotherapy to specific problems. *Osteo Med.* August 1977;79-81,85,86,89-91,94-96.
69. Leriche R. Effets de l'anesthésie A la novocaine des ligaments et des insertions tendineuses periarticulaires dans certaines maladies articulaires et dans les vices des positions fonctionnelles des articulations. *Gaz Hop.* 1930;103:1294.
70. Linetsky FS, Mikulinsky A, Gorfine L. Regenerative injection therapy: history of application in pain management: Part I, 1930s-1950s. *Pain Clin.* 2000;2:8-13.
71. Liu Y, Tipton CM, Matthes RD, Bedford TG, Maynard JA, Walmer HC. An in situ study of the influence of a sclerosing solution in rabbit medial collateral ligaments and its junction strength. *Conn Tissue Res.* 1983;11: 95-102.
72. Maher RM. Neurone selection in relief of pain. Further experiences with intrathecal injections. *Lancet.* January 1957;16-19.
73. Marui T, Niyibizi C, Georgescu HI, et al. Effect of growth factors on matrix synthesis by ligament fibroblasts. *J Orthop Res.* 1997;15:18-23.
74. Massie J, Mooney V, Green DA. Is it possible to stimulate fibroplasia within the intervertebral disc? *J Orthop Med.* 1993;15:83.
75. Matthews JH. A new approach to the treatment of osteoarthritis of the knee: prolotherapy of the ipsilateral sacroiliac ligaments. *Am J Pain Manage.* 1995; 5:91-93.
76. Maynard JA, Pedrini VA, PedrineMille A, Romanus B, Ohlerking F. Morphological and biochemical effects of sodium morrhuate on tendons. *J Orthop Res.* 1985;3:236-248.
77. Mirman M. *Sclerotherapy.* 4th ed. Springfield, Pa: Mirman; 1989.
78. Mooney V. Sclerotherapy in back pain? Yes, if clinician is skilled. *J Musculoskel Med.* January 1993:13.
79. Mooney V. Understanding, examining for, and treating sacroiliac pain. *J Musculoskel Med.* July 1993:37-49.
80. Myers A. Prolotherapy treatment of low back pain and sciatica. *Bull Hosp Joint Dis.* 1961;22:48-55.
81. Neff F. A new approach in the treatment of chronic back disabilities. *Fam Phys.* 1959;9:3.
82. Neff F. Low back pain and disability. *West Med.* 1960;1:12.
83. Ombregt L, Bisschop P, ter Veer HJ, Van de Velde T. *A System of Orthopaedic Medicine.* Philadelphia, Pa: WB Saunders; 1995.
84. Ongley MJ, Dorman TA, Klein RG, Eek BC, Hubert LJ. A new approach to the treatment of chronic low back pain. *Lancet.* July 1987:143-146.
85. Ongley MJ, Dorman TA, Eek BC, Lundgren D, Klein RG. Ligament instability of knees: A new approach to treatment. *Manual Med.* 1988;3:152-154.
86. Poritt A. The injection treatment of hydrocele, varicocele, bursae and nevi. *Proc Royal Soc Med.* 1931;24:81.
87. Reeves KD, Hassanein K. Randomized prospective double-blind placebo-controlled study of dextrose prolotherapy for knee osteoarthritis with or without ACL laxity. *Ahern Ther Health Med.* 2000;6:68-74,77-80.
88. Reeves KD, Hassanein K. Randomized, prospective, placebo-controlled double-blind study of dextrose prolotherapy for osteoarthritic thumb and finger joints: evidence of clinical efficacy. *J Altern Complement Med.* 2000;6:311-320.
89. Reeves KD. Treatment of consecutive severe fibromyalgia patients with prolotherapy. *J Orthop Med.* 1994;16:84-89.
90. Riddle P. *Injection Treatment of Hernia, Hydrocele, Ganglion, Hemorrhoids, Prostate Gland, Angioma, Varicocele, Varicose Veins, Bursae and Joints.* Philadelphia, Pa: WB Saunders; 1940.
91. Schultz L. A treatment for subluxation of the temporomandibular joint. *JAMA.* 1937;256:1032-1035.
92. Schultz L. Twenty years' experience in treating hypermobility of the temporomandibular joints. *Am J Surg.* 1956;92: 925-928.
93. Schwartz R, Sagedy N. Prolotherapy: a literature review and retrospective study. *J Neurol Orthop Med Surg.* 1991; 12:220-223.
94. Shuman D. *Low Back Pain.* Philadelphia, Pa: David Shuman; 1958.
95. Shuman D. Luxation recurring in shoulder. *Osteo Prof* 1941;8:11-13.
96. Shuman D. Sclerotherapy: injections may be best way to restrengthen ligaments in case of slipped knee cartilage. *Osteo Prof.* March 1949.
97. Shuman D. The place of joint sclerotherapy in today's practice. *Bull NJ Assoc Osteo Phys Surg.* October 1949.
98. Shuman D. Sclerotherapy: statistics on its effectiveness for unstable joint conditions. *Osteo Prof.* 1954;21:11-15, 37-38.
99. Vanderschot L. Trigger points vs acupuncture points. *Intl J Acupunc.* 1976;4:233-238.
100. Vlemming A, Mooney V, Dorman T, Snijders C, Stoeckart R. *Movement, Stability and Low Back Pain: The Essential Role of the Pelvis.* New York, NY: Churchill Livingstone; 1997.
101. Wilkinson HA. *The Failed Back Syndrome Etiology and Therapy.* 2nd ed. New York, NY: Springer-Verlag; 1992.
102. Cousins MJ, Fink R, Bridenbaugh PO, et al. *Neural Blockage in Clinical Anesthesia and Management of Pain.* Philadelphia, Pa: JB Lippincott Co; 1988.
103. Roosth H. Low back and leg pain attributed to gluteal tendinosis. *Orthop*



- Today*. November 1991:10.
104. Vanderschot L. The American version of acupuncture. Prolotherapy: coming to an understanding. *Am J Acupunct*. 1976;4:309-316.
105. Leadbetter W. Cell-matrix response in tendon injury. *Clin Sports Med*. 1992; 11:533-578.
106. Leadbetter W. Anti-inflammatory therapy in sports injury: The role of non-steroidal drugs and corticosteroid injection. *Clin Sports Med*. 1995;14:353-410.
107. Leadbetter W. *Soft Tissue Athletic Injuries-Sports Injuries: Mechanisms, Prevention, Treatment*. Philadelphia, Pa: Williams & Wilkins; 1994:736-737.
108. Best T. Basic science of soft tissue. In: Delee JC, Drez D Jr, eds. *Orthopedic Sports Medicine Principles and Practice*. Philadelphia, Pa: WB Saunders; 1994;1: 7-35.
109. Shevelev OA, Sokov EL, Klepikov RV. Interosseous receptor system as the modulator of trigeminal afferent reactions. *Pain Clin*. 2000;34:715-721.
110. Sokov E, Mustafa A. Are herniated disks the main cause of low back pain. *Pain Clin*. 2000;74:715-721.
111. Zoppi M, Beneforti E. From intra-osseous pain syndrome to osteoarthritis. *Worldwide Pain Conference. Pain and Neuromodulation: The New Millennium*. Proceedings of the 9th World Congress. The Pain Clinic. July 2000; San Francisco, Calif.
112. Agur A, Lee MJ. *Grants Atlas of Anatomy*. 9th ed. Baltimore, Md. Williams & Wilkins; 1991.
113. Aprill C, Dwyer A, Bogduk N. Cervical zygapophyseal joint pain patterns 11: a clinical evaluation. *Spine*. 1990;15:458-461.
114. Ashton IK, Ashton BA, Gibson SJ, Polak JM, Jaffray DC, Eisenstein SM. Morphological basis for back pain: the demonstration of nerve fibers and neuropeptides in the lumbar facet joint capsule but not in ligamentum flavum. *J Orthop Res*. 1992;10:72-77.
115. Barnsley L, Lord SM, Wallis BJ, Bogduk N. Lack of effect of intra-articular corticosteroids for chronic pain in the cervical zygapophyseal joints. *N Engl J Med*. 1994;330:1047-1050.
116. Bogduk N. *Clinical Anatomy of the Lumbar Spine and Sacrum*. 3rd ed. New York, NY: Churchill Livingstone; 1997.
117. Broadhurst NA, Wilk VJ. Vertebral mid-line pain: pain arising from the interspinous spaces. *J Orthop Med*. 1996; 18:2-4.
118. Cyriax J. *Illustrated Manual of Orthopaedic Medicine*. 2nd ed. Oxford, England. Butterworth Heinemann; 1993.
119. DesRosiers EA, Yahia L, Rivard C. Proliferative and matrix synthesis response of canine anterior cruciate ligament fibroblasts submitted to combined growth factors. *J Orthop Res*. 1996; 14:200-208.
120. Dreyfuss P, Michaelsen M, Fletcher D. Atlanto-occipital and lateral atlanto-axial joint pain patterns. *Spine*. 1994; 19:1125-1131.
121. Dreyfuss P, Tibiletti C, Dreyer SJ. Thoracic zygapophyseal joint pain patterns: a study in normal volunteers. *Spine*. 1994; 19:807-811.
122. Dreyfuss P. Differential diagnosis of thoracic pain and diagnostic/therapeutic injection techniques. *ISIS Newsletter* 1997:10-29.
123. Dreyfuss P, Michaelsen M, Home M. MUJA: manipulation under joint anesthesia/analgesia: a treatment approach for recalcitrant low back pain of synovial joint origin. *J Manipulative ve Physiol Ther* October 1995;18:537-546.
124. Dussault R, Kaplan PA. Facet joint injection: diagnosis and therapy. *Appl Radiol*. June 1994:35-39.
125. Dwyer A, Aprill C, Bogduk N. Cervical zygapophyseal joint pain patterns I: a study in normal volunteers. *Spine*. 1990;15:453-457.
126. Freemont A. Nerve ingrowth into diseased intervertebral disc in chronic back pain. *Lancet*. 1997;350:178-181.
127. Hunt WE, Baird WC. Complications following injection of sclerosing agent to precipitate fibro-osseous proliferation. *J Neurourg*. 1981;18:461-465.
128. Jozsa LG, Kannus P. *Human Tendons: Anatomy, Physiology and Pathology*. 1st ed. Champaign, 111: Human Kinetics; 1997.
129. *Dorland's Illustrated Medical Dictionary*. 28th ed. Philadelphia, Pa: WB Saunders; 1994.
130. Merskey H, Bogduk N. *Classification of Chronic Pain, Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms*. 2nd ed. Seattle, Wash: IASP Press; 1994.
131. Ranney D. *Chronic Musculoskeletal Injuries in the Workplace*. Philadelphia, Pa: WB Saunders; 1997.
132. Kang HJ, Kang ES. Ideal concentration of growth factors in rabbit's flexor tendon culture. *Yonsei Med J*. 1999; 40:26-29.

THE FLORIDA ACADEMY OF
PAIN MEDICINE

3807 NW 53rd Terrace
Gainesville, FL 32606
(352) 372-9360

Become a member of the Florida Academy of Pain Medicine today to take advantage of a broad range of membership benefits, including: Discounted registration at educational conferences, important legal and regulatory updates, advocacy on billing and reimbursement issues, and the opportunity to network with colleagues from a wide variety of specialties. For more information, contact the FAPM headquarters at (352) 372-9360.

2001-2002 BOARD OF DIRECTORS

President - Andrea M. Trescot, MD
President-elect - Gary W. Jay, MD
Secretary - Winston Parris, MD
Vice President -
Francisco M. Torres, MD
Treasurer - Kenneth P. Botwin, MD
Legislative Committee Chair -
Sanford Z. Pollack, DO
Membership Committee -
James J. Worden, MD
Past President -
James B. Boorstin, MD
Immediate Past President -
Felix S. Linetsky, MD